FOLH1 and neoplasm: Multidose of 64Cu-DOTHA2-PSMA could have an impact on tumor size control and toxicity, based on dose fractionation principles and similarly to previously published preclinical results with 64Cu and 177Lu and to 177Lu-PSMA-617 clinical protocols (14, 23–25, 27–30).